指南与共识消化内镜

美国内镜指南作者未披露的医药与器械制造商支付情况

Undisclosed payments by pharmaceutical and medical device manufacturers to authors of endoscopy guidelines in the United States.
指南 / 共识 · Gastrointest Endosc · 2019-11-15

结果显示79%的作者条目存在未披露的财务利益冲突,中位未披露支付金额为4807.26美元,男性及学术机构作者更可能出现未披露支付,且无指南完全符合美国国家医学院标准。

要点

  • 内镜指南作者中79%存在未披露的行业财务利益冲突。
  • 中位未披露支付金额为4807.26美元(IQR $334.84-$20,579.75)。
  • 男性及学术机构作者未披露支付的风险显著更高。

核心结论

  • 行业报告的支付与作者自我披露之间存在显著差异,未披露支付普遍存在。
  • 需要更准确的报告和替代性策略来管理财务利益冲突。

研究设计与样本

  • 通过指南披露部分和CMS-OP数据库识别支付,评估发布当年及前一年的支付情况。

主要发现

  • 451条(79%)作者条目存在财务利益冲突,451条(79%)在CMS-OP中有未披露的财务利益冲突。
  • 445条(77%)存在与指南推荐相关的财务利益冲突。
  • 未披露支付中位值为4807.26美元(IQR $334.84-$20,579.75)。
  • 男性作者(OR 2.23;95%CI 1.47-3.39)和学术机构作者(OR 8.87;95%CI 5.57-14.13)更可能有未披露支付(P < .001)。
  • 无指南满足美国国家医学院所有标准。

关键数值与推荐

  • 未披露支付中位值4807.26美元(IQR $334.84-$20,579.75)。
  • 男性作者OR 2.23(95%CI 1.47-3.39),学术机构作者OR 8.87(95%CI 5.57-14.13),P < .001。

临床怎么用

  • 消化内科医生在采纳内镜指南推荐时应意识到作者未披露财务利益冲突的高 prevalence 及潜在影响。
  • 指南制定机构应加强财务利益冲突披露的准确性和管理策略。

局限性

  • 承认对CMS-OP数据库准确性的担忧。
  • 分析仅基于CMS-OP数据库和指南披露部分,可能存在未捕获的支付。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Payments from pharmaceutical and medical device manufacturers to authors of clinical practice guidelines (CPGs) may influence practice recommendations. It is therefore important to evaluate the completeness of financial conflict of interest (FCOI) declarations among CPG authors. METHODS: We performed a cross-sectional analysis of industry payments to authors of endoscopy guidelines published by 5 GI societies between 2014 and 2017. For each author we identified payments using the disclosure section of CPGs and the Centers for Medicare & Medicaid Services Open Payments (CMS-OP) database. We calculated the prevalence, monetary value, and type of declared and undeclared payments among authors. Payments were assessed for the calendar year of and before publication. RESULTS: Thirty-seven CPGs were included in the analysis comprising 569 author entries (91 unique individuals; 66.43% men, 92.6% physicians, 66.4% academically affiliated). Four hundred fifty-one episodes (79%) involved FCOIs, 451 (79%) had undisclosed FCOIs in the CMS-OP, and 445 (77%) had FCOIs relevant to a CPG recommendation. The median undisclosed payment value was $4807.26 (interquartile range, $334.84-$20,579.75). Male authors (odds ratio, 2.23; 95% confidence interval, 1.47-3.39) and academically affiliated authors (odds ratio, 8.87; 95% confidence interval, 5.57-14.13) were significantly more likely to have undeclared payments (P < .001). No CPGs met all National Academy of Medicine criteria. CONCLUSIONS: Recognizing concerns about the accuracy of the CMS-OP, there are substantial discrepancies between industry-reported payments and author self-disclosure. Additionally, there is a high prevalence of undisclosed payments by pharmaceutical and medical device manufacturers to these authors. Given the potential impact of these discrepancies and undisclosed payments on CPGs, more accurate reporting and alternative strategies for managing FCOI are needed.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Bansal R, Khan R, Scaffidi MA, et al. Undisclosed payments by pharmaceutical and medical device manufacturers to authors of endoscopy guidelines in the United States. Gastrointest Endosc. 2019. PMID: 31738925. doi:10.1016/j.gie.2019.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。